Now that Bristol Myers Squibb Company has the maximum fair price (MFP) in hand that Medicare intends to pay for Eliquis (apixaban) starting in 2026 under the drug price negotiation authority granted by the Inflation Reduction Act (IRA), CEO Chris Boerner said the company is “increasingly confident in our ability to navigate the impact of IRA on Eliquis.”
BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis
Pharma To Announce IRA-Mandated Final Price Soon
Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.
More from Drug Pricing
• By
Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?
• By
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
• By
Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.
• By
Policy advances, measures to back local production and crowdfunding action for gene therapies like Zolgensma bring hope for rare disease patients in India. Gaps in financing, high prices and an ongoing court case, however, stunt efforts to ensure timely access.
More from Scrip
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.